DK1732917T3 - Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel - Google Patents

Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel

Info

Publication number: DK1732917T3
Authority: DK; Denmark
Prior art keywords: drug; processes; preparation; cgrp antagonists; selected cgrp
Prior art date: 2004-03-29

Application number

DK05741783T

Other languages

Danish (da)

English (en)

Inventor

Gerhard Schaenzle

Fabio Paleari

Philipp Lustenberger

Marco Santagostino

Stephan Georg Mueller

Klaus Rudolf

Dirk Stenkamp

Alexander Dreyer

Kirsten Arndt

Henri Doods

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-29

Filing date

2005-03-23

Publication date

2009-11-30

2005-03-23 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2009-11-30 Application granted granted Critical

2009-11-30 Publication of DK1732917T3 publication Critical patent/DK1732917T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Addiction (AREA)
Dermatology (AREA)
Hematology (AREA)
Immunology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)

DK05741783T 2004-03-29 2005-03-23 Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel DK1732917T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004015723A DE102004015723A1 (de)	2004-03-29	2004-03-29	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP2005/003094 WO2005092880A1 (de)	2004-03-29	2005-03-23	Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
DK1732917T3 true DK1732917T3 (da)	2009-11-30

Family

ID=34967621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05741783T DK1732917T3 (da)	2004-03-29	2005-03-23	Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel

Country Status (32)

Country	Link
US (3)	US7479488B2 (es)
EP (2)	EP1732917B8 (es)
JP (2)	JP4796567B2 (es)
KR (1)	KR20070007867A (es)
CN (1)	CN1976916A (es)
AR (2)	AR049625A1 (es)
AT (2)	ATE437868T1 (es)
AU (1)	AU2005225539A1 (es)
BR (2)	BRPI0509368A (es)
CA (1)	CA2558889A1 (es)
CY (2)	CY1108744T1 (es)
DE (2)	DE102004015723A1 (es)
DK (1)	DK1732917T3 (es)
EA (1)	EA012111B1 (es)
EC (1)	ECSP066898A (es)
ES (1)	ES2330865T3 (es)
HR (1)	HRP20090457T1 (es)
IL (2)	IL178334A0 (es)
MX (1)	MX2007011526A (es)
MY (1)	MY141754A (es)
NO (1)	NO20064166L (es)
NZ (2)	NZ550774A (es)
PE (2)	PE20060150A1 (es)
PL (1)	PL1732917T3 (es)
PT (1)	PT1732917E (es)
RS (1)	RS51150B (es)
SI (1)	SI1732917T1 (es)
TW (1)	TW200602338A (es)
UA (1)	UA88163C2 (es)
UY (1)	UY29437A1 (es)
WO (1)	WO2005092880A1 (es)
ZA (2)	ZA200606056B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7220862B2 (en)	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
DK1539766T3 (en) *	2002-06-05	2017-04-03	Bristol Myers Squibb Co	CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
US7842808B2 (en)	2002-06-05	2010-11-30	Bristol-Myers Squibb Company	Anti-migraine spirocycles
DE10250082A1 (de) *	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) *	2002-10-25	2009-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200524601A (en)	2003-12-05	2005-08-01	Bristol Myers Squibb Co	Heterocyclic anti-migraine agents
DE102004015723A1 (de)	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en)	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
US7696195B2 (en)	2004-04-22	2010-04-13	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) *	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7384931B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en)	2004-12-03	2008-11-11	Bristol-Myers Squibb Company	Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063753A1 (de) *	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) *	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US7491717B2 (en) *	2005-03-23	2009-02-17	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770091A1 (de) *	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7439237B2 (en) *	2005-04-15	2008-10-21	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) *	2005-08-17	2007-02-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en)	2005-08-25	2010-11-16	Bristol-Myers Squibb Company	CGRP antagonists
EP1770086A1 (de)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005050892A1 (de) *	2005-10-21	2007-04-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
SI1957106T2 (sl)	2005-11-14	2019-09-30	Teva Pharmaceuticals International Gmbh	Antagonistna protitelesa, usmerjena proti peptidu, povezanemu s kalcitoninskim genom, in postopki za njihovo uporabo
DE102006017827A1 (de) *	2006-04-13	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue kristalline Verbindungen
CA2654048A1 (en) *	2006-06-08	2007-12-13	Boehringer Ingelheim International Gmbh	Treatment of gastrointestinal disorders with cgrp antagonists
DE102006039038A1 (de) *	2006-08-19	2008-02-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neues Herstellungsverfahren
US7662057B2 (en) *	2007-06-08	2010-02-16	Schaeffler Kg	Eccentric tensioning device
DE102007038250A1 (de) *	2007-08-13	2009-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neues Herstellverfahren
RU2522493C2 (ru)	2008-03-04	2014-07-20	Пфайзер Лимитед	Способы лечения хронической боли
JP5745861B2 (ja) *	2008-03-04	2015-07-08	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	炎症性疼痛を治療する方法
WO2011024113A1 (en)	2009-08-28	2011-03-03	Rinat Neuroscience Corporation	Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
SMT202400511T1 (it)	2011-05-20	2025-01-14	H Lundbeck As	Uso di anticorpi anti-cgrp e frammenti di anticorpi per prevenire o inibire la fotofobia o l'avversione alla luce in soggetti che ne hanno bisogno, in particolare nei soggetti che soffrono di emicrania
EA033109B1 (ru)	2011-05-20	2019-08-30	Олдербайо Холдингз Ллк	Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
CN107602700B (zh)	2011-05-20	2021-12-17	H.伦德贝克公司	抗cgrp组合物及其用途
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2015143409A1 (en)	2014-03-21	2015-09-24	Labrys Biologics, Inc.	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
SG10201913032TA (en)	2016-09-23	2020-02-27	Teva Pharmaceuticals Int Gmbh	Treating refractory migraine
PH12021551478A1 (en)	2019-01-08	2022-05-02	H Lundbeck As	Acute treatment and rapid treatment of headache using anti-cgrp antibodies
WO2022185224A1 (en)	2021-03-02	2022-09-09	Mark Hasleton	Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW209870B (es)	1990-01-18	1993-07-21	Pfizer
US5442044A (en)	1991-01-04	1995-08-15	Pfizer Inc.	Orally active renin inhibitors
CA2137832C (en)	1992-06-12	2000-09-26	Dennis J. Hoover	Inhibitors of angiotensin i chymase(s) including human heart chymase
US5798337A (en)	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
JP2000511527A (ja)	1996-05-22	2000-09-05	ワーナー―ランバート・コンパニー	タンパク質ファルネシルトランスフェラーゼの阻止
US6300501B1 (en)	1996-05-22	2001-10-09	Warner-Lambert Company	Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
JP2001500850A (ja)	1996-08-22	2001-01-23	ワーナー―ランバート・コンパニー	非―ペプチドボンベシン受容体アンタゴニスト
BR9712023A (pt)	1996-09-10	1999-08-31	Thomae Gmbh Dr K	Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
US6025372A (en)	1997-04-04	2000-02-15	Merck & Co., Inc.	Somatostatin agonists
US20030069231A1 (en) *	1999-10-12	2003-04-10	Klaus Rudolf	Modified aminoacids, pharmaceuticals containing these compounds and method for their production
EP1117662A1 (en)	1998-09-30	2001-07-25	Merck Sharp & Dohme Limited	Benzimidazolinyl piperidines as cgrp ligands
DE19911039A1 (de)	1999-03-12	2000-09-14	Boehringer Ingelheim Pharma	Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6313097B1 (en)	1999-03-02	2001-11-06	Boehringer Ingelheim Pharma Kg	Antagonists of calcitonin gene-related peptide
US6521609B1 (en)	1999-08-10	2003-02-18	Boehringer Ingelheim Pharma Kg	Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
DE19937304C2 (de)	1999-08-10	2003-08-21	Boehringer Ingelheim Pharma	Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE19952146A1 (de)	1999-10-29	2001-06-07	Boehringer Ingelheim Pharma	Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6653478B2 (en)	2000-10-27	2003-11-25	Ortho-Mcneil Pharmaceutical, Inc.	Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
US6900317B2 (en)	2002-02-19	2005-05-31	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (de)	2002-02-19	2003-08-28	Boehringer Ingelheim Pharma	Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
DE10211770A1 (de)	2002-03-14	2003-10-02	Boehringer Ingelheim Pharma	Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en)	2002-03-14	2006-04-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DK1539766T3 (en)	2002-06-05	2017-04-03	Bristol Myers Squibb Co	CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
US7220862B2 (en)	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
DE10227294A1 (de)	2002-06-19	2004-01-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
US20040076587A1 (en)	2002-06-19	2004-04-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical composition for intranasal administration containing a CGRP antagonist
US7595312B2 (en)	2002-10-25	2009-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) *	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) *	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de)	2003-01-14	2004-07-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2005084672A1 (de)	2004-03-03	2005-09-15	Boehringer Ingelheim International Gmbh	Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
TW200533398A (en)	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de)	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en)	2004-04-15	2007-10-09	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018796A1 (de)	2004-04-15	2005-11-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050282857A1 (en)	2004-04-15	2005-12-22	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018795A1 (de)	2004-04-15	2005-10-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en)	2004-04-22	2010-04-13	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de)	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063753A1 (de)	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063755A1 (de)	2004-12-29	2006-07-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de)	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US7491717B2 (en)	2005-03-23	2009-02-17	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CN101146799A (zh) *	2005-03-23	2008-03-19	贝林格尔·英格海姆国际有限公司	Cgrp拮抗剂、其制备方法以及其作为药物的用途
EP1770091A1 (de)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005038831A1 (de)	2005-08-17	2007-02-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005050892A1 (de)	2005-10-21	2007-04-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

2004
- 2004-03-29 DE DE102004015723A patent/DE102004015723A1/de not_active Withdrawn
2005
- 2005-03-23 PL PL05741783T patent/PL1732917T3/pl unknown
- 2005-03-23 JP JP2007505453A patent/JP4796567B2/ja not_active Expired - Fee Related
- 2005-03-23 AT AT05741783T patent/ATE437868T1/de active
- 2005-03-23 BR BRPI0509368-6A patent/BRPI0509368A/pt not_active IP Right Cessation
- 2005-03-23 AU AU2005225539A patent/AU2005225539A1/en not_active Abandoned
- 2005-03-23 PE PE2005000336A patent/PE20060150A1/es not_active Application Discontinuation
- 2005-03-23 PT PT05741783T patent/PT1732917E/pt unknown
- 2005-03-23 KR KR1020067022593A patent/KR20070007867A/ko not_active Application Discontinuation
- 2005-03-23 RS RSP-2009/0374A patent/RS51150B/sr unknown
- 2005-03-23 WO PCT/EP2005/003094 patent/WO2005092880A1/de active Application Filing
- 2005-03-23 CN CNA2005800175452A patent/CN1976916A/zh active Pending
- 2005-03-23 SI SI200530817T patent/SI1732917T1/sl unknown
- 2005-03-23 PE PE2009001130A patent/PE20091884A1/es not_active Application Discontinuation
- 2005-03-23 DK DK05741783T patent/DK1732917T3/da active
- 2005-03-23 EP EP05741783A patent/EP1732917B8/de active Active
- 2005-03-23 NZ NZ550774A patent/NZ550774A/en unknown
- 2005-03-23 ES ES05741783T patent/ES2330865T3/es active Active
- 2005-03-23 DE DE502005007786T patent/DE502005007786D1/de active Active
- 2005-03-23 EA EA200601621A patent/EA012111B1/ru not_active IP Right Cessation
- 2005-03-23 CA CA002558889A patent/CA2558889A1/en not_active Abandoned
- 2005-03-23 AR ARP050101139A patent/AR049625A1/es unknown
- 2005-03-23 UA UAA200611256A patent/UA88163C2/ru unknown
- 2005-03-23 EP EP09160781A patent/EP2108648A1/de not_active Withdrawn
- 2005-03-25 MY MYPI20051328A patent/MY141754A/en unknown
- 2005-03-28 TW TW094109570A patent/TW200602338A/zh unknown
- 2005-03-29 US US11/093,834 patent/US7479488B2/en active Active
2006
- 2006-03-21 AT AT06723571T patent/ATE414074T1/de active
- 2006-03-21 MX MX2007011526A patent/MX2007011526A/es active IP Right Grant
- 2006-03-21 BR BRPI0608929-1A patent/BRPI0608929A2/pt not_active IP Right Cessation
- 2006-03-21 NZ NZ562537A patent/NZ562537A/en not_active IP Right Cessation
- 2006-03-22 UY UY29437A patent/UY29437A1/es not_active Application Discontinuation
- 2006-03-22 AR ARP060101117A patent/AR053344A1/es unknown
- 2006-07-21 ZA ZA200606056A patent/ZA200606056B/xx unknown
- 2006-09-14 NO NO20064166A patent/NO20064166L/no not_active Application Discontinuation
- 2006-09-27 IL IL178334A patent/IL178334A0/en unknown
- 2006-09-29 EC EC2006006898A patent/ECSP066898A/es unknown
2007
- 2007-07-18 ZA ZA200705879A patent/ZA200705879B/xx unknown
- 2007-09-20 IL IL186089A patent/IL186089A0/en unknown
2008
- 2008-04-07 JP JP2008099425A patent/JP2008189689A/ja not_active Withdrawn
- 2008-10-06 US US12/246,067 patent/US7700598B2/en active Active
2009
- 2009-02-04 CY CY20091100128T patent/CY1108744T1/el unknown
- 2009-08-25 HR HR20090457T patent/HRP20090457T1/hr unknown
- 2009-10-26 CY CY20091101109T patent/CY1109510T1/el unknown
2010
- 2010-02-25 US US12/712,801 patent/US20100249114A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1732917B1 (de)	2009-07-29
PE20091884A1 (es)	2009-12-20
EP1732917A1 (de)	2006-12-20
PL1732917T3 (pl)	2010-03-31
UY29437A1 (es)	2006-10-31
SI1732917T1 (sl)	2010-01-29
AR053344A1 (es)	2007-05-02
KR20070007867A (ko)	2007-01-16
PT1732917E (pt)	2009-09-29
ATE437868T1 (de)	2009-08-15
CY1108744T1 (el)	2014-04-09
JP4796567B2 (ja)	2011-10-19
EA200601621A1 (ru)	2007-04-27
ES2330865T3 (es)	2009-12-16
CN1976916A (zh)	2007-06-06
DE502005007786D1 (de)	2009-09-10
ATE414074T1 (de)	2008-11-15
US20100249114A1 (en)	2010-09-30
RS51150B (sr)	2010-10-31
TW200602338A (en)	2006-01-16
NZ550774A (en)	2010-10-29
AR049625A1 (es)	2006-08-23
IL178334A0 (en)	2007-02-11
JP2008189689A (ja)	2008-08-21
JP2007530617A (ja)	2007-11-01
US7479488B2 (en)	2009-01-20
MY141754A (en)	2010-06-30
CA2558889A1 (en)	2005-10-06
US20090176770A1 (en)	2009-07-09
ZA200606056B (en)	2009-09-30
ZA200705879B (en)	2009-01-28
EP1732917B8 (de)	2009-09-09
HRP20090457T1 (hr)	2009-10-31
CY1109510T1 (el)	2014-08-13
BRPI0509368A (pt)	2007-09-11
NZ562537A (en)	2009-10-30
BRPI0608929A2 (pt)	2010-02-17
US20050234067A1 (en)	2005-10-20
US7700598B2 (en)	2010-04-20
ECSP066898A (es)	2006-12-29
DE102004015723A1 (de)	2005-10-20
NO20064166L (no)	2006-10-25
PE20060150A1 (es)	2006-04-04
EA012111B1 (ru)	2009-08-28
IL186089A0 (en)	2008-01-20
EP2108648A1 (de)	2009-10-14
MX2007011526A (es)	2007-10-19
WO2005092880A1 (de)	2005-10-06
AU2005225539A1 (en)	2005-10-06
UA88163C2 (ru)	2009-09-25

Publication	Publication Date	Title
DK1732917T3 (da)	2009-11-30	Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel
DK1558600T3 (da)	2008-09-01	Udvalgte CGRP-antagonister, fremgangsmåder til fremstilling deraf samt deres anvendelse som lægemiddel
NO20052739D0 (no)	2005-06-07	CCR5-antagonister som medikamenter
NO20052493D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
DE602005024200D1 (de)	2010-12-02	Stent zum Abgeben von Medikamenten
DK1907037T3 (da)	2019-10-21	Medikamentdispenser.
ZA200800431B (en)	2009-05-27	Selected cgrp antagonists, methods for the production thereof and their use as medicaments
IL186090A0 (en)	2008-01-20	Cgrp antagonists, method for the production thereof, and their use as medicaments
DK1740177T3 (da)	2012-10-29	Antagonister til muskarinfølsomme acetylcholinreceptorer
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
DK2110150T3 (da)	2012-01-02	Fremgangsmåde til bestemmelse af medikamentmængden, som er indholdt i en medikamentbeholder
DK1781656T3 (da)	2008-05-05	Arylsucbstituerede polycykliske aminer, fremgangsmåde til fremstilling heraf samt anvendelse heraf som lægemiddel
DE602005026188D1 (de)	2011-03-17	Medikamentenspender
DK1830907T3 (da)	2009-08-10	Hætte til lægemiddelfrigivelsesanordninger
DK1898863T3 (da)	2011-08-29	Etui til optagelse af en lægemiddelspakning samt anvendelse deraf
IL189497A0 (en)	2008-08-07	Selected cgrp antagonists, methods for the production thereof and their use as medicaments
DK1711465T3 (da)	2008-03-31	Hydroisoindolin-tachykinikreceptorantagonister
FI20041129A0 (fi)	2004-08-30	Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
DK1831240T3 (da)	2009-11-23	18-methyl-19-nor-17pregn-4-en-21, 17-carbolactoner samt farmaceutiske præparater, der indeholder disse
DK1773796T3 (da)	2010-06-21	Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
DK1729819T3 (da)	2008-10-20	Indgivelsesanordning til lægemidler, som er röntgenstråle-synlige
EP1992349B8 (de)	2013-10-09	CGRP-antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DK2918286T3 (da)	2020-03-30	En farmaceutisk formulering
DE502005002048D1 (de)	2008-01-03	Schmales, seitlich eng aneinanderreihbares wägesystem
DK1720557T3 (da)	2011-02-14	Hurtig-opløselig, smagsmaskeret tablet